Robert J. Soiffer

Active 1990–2025

Also published as
Robert J Soiffer
234
Papers
37,665
Citations
115
h-index
226
i10-index

Citations

Citations per year for Robert J. Soiffer1948: 1 citations1983: 1 citations1984: 1 citations1991: 6 citations1992: 9 citations1993: 16 citations1994: 16 citations1995: 12 citations1996: 14 citations1997: 18 citations1998: 23 citations1999: 33 citations2000: 59 citations2001: 57 citations2002: 97 citations2003: 122 citations2004: 113 citations2005: 169 citations2006: 187 citations2007: 206 citations2008: 222 citations2009: 216 citations2010: 251 citations2011: 231 citations2012: 278 citations2013: 265 citations2014: 338 citations2015: 369 citations2016: 365 citations2017: 336 citations2018: 297 citations2019: 1,120 citations2020: 1,168 citations2021: 1,147 citations2022: 867 citations2023: 707 citations2024: 1,150 citations2025: 546 citations2026: 10 citations1949–1982: no citations, so these years are not shown1985–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,315 citing papers, 32.3% of this breakdownGermany: 998 citing papers, 7.5% of this breakdownUnited Kingdom: 786 citing papers, 5.9% of this breakdownChina: 739 citing papers, 5.5% of this breakdownFrance: 720 citing papers, 5.4% of this breakdownItaly: 711 citing papers, 5.3% of this breakdownSpain: 450 citing papers, 3.4% of this breakdownCanada: 436 citing papers, 3.3% of this breakdownNetherlands: 419 citing papers, 3.1% of this breakdownJapan: 390 citing papers, 2.9% of this breakdownAustralia: 311 citing papers, 2.3% of this breakdownSwitzerland: 287 citing papers, 2.1% of this breakdown
0%32.3%Other 21%

Fields

  • Medicine71.3%
  • Immunology and Microbiology19.1%
  • Biochemistry, Genetics and Molecular Biology7.5%
  • Neuroscience0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • Computer Science0.2%
  • Other1.1%

Topics

  • Hematopoietic Stem Cell Transplantation11.2%
  • Immune Cell Function and Interaction7.8%
  • Acute Myeloid Leukemia Research7.1%
  • T-cell and B-cell Immunology5.7%
  • CAR-T cell therapy research4.8%
  • Immunotherapy and Immune Responses4%
  • Other59.4%

Coauthors

All papers

Open in search
  1. Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

    Authors: , , , , , , , , , , , , , , , , , , - NEJM Evidence 2023 cited by 295

  2. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Immunology Research 2018 cited by 325

  3. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 470

  4. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jason E. Hill, Stanley C. Gill, Rishita Nuthethi, Denise King, Heather Wittsack, Adam Mendizabal, Steven M. Devine, Mary M. Horowitz, Yi‐Bin Chen, on behalf of the BMT-CTN 1506/MORPHO Study Investigators, Ed Agura, Jessica K. Altman, Achiles Anagnostopoulos, Sarah Anand, Andrew Artz, Walter E. Aulitzky, Sophia Balderman, Karen K. Ballen, Michael W. Becker, Yves Béguin, Leanne Berkahn, Zwi Berneman, Vijaya Raj Bhatt, Ian Bilmon, Francesca Bonifazi, Adrienne Briggs, Benedetto Bruno, Claudio G. Brunstein, Michael Byrne, Jenny Byrne, Mónica Cabrero, Roberto Cairoli, George Carrum, Jan Černý, Yi‐Bin Chen, June‐Won Cheong, Fabio Ciceri, Mercedes Colorado, Rachel J. Cook, Daniel R. Couriel, Charles Craddock, Lloyd E. Damon, Abhinav Deol, Yohan Desbrosses, Steve Devine, Carmela Di Grazia, Antonio Di Stasi, Ajoy Dias, Kathy Dorritie, James Essell, Tetsuya Eto, Sherif S. Farag, Édouard Forcade, Olga Frankfurt, Shin‐ichiro Fujiwara, Takahiro Fukuda, Kentaro Fukushima, Sabine Fürst, Tatsunori Goto, Aric C. Hall, Shunsuke Hatta, Yosr Hicheri, Mitchell E. Horwitz, Hsin‐An Hou, Jonathan How, Dianna S. Howard, Wei‐Hsun Hsu, Anne Huynh, David Irvine, Takayuki Ishikawa and 109 more - Journal of Clinical Oncology 2024 cited by 185

  5. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2022 cited by 132

  6. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2011 cited by 1,117

  7. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jerome Ritz, Rizwan Romee - Journal of Clinical Investigation 2022 cited by 138

  8. Ipilimumab for Patients with Relapse after Allogeneic Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Asad Bashey, Robert J. Soiffer - New England Journal of Medicine 2016 cited by 594

  9. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

    Authors: , , , , , , , , , , , , - Blood 2014 cited by 942

  10. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 168

  11. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul G. Richardson, Jerome Ritz, Benjamin L. Ebert, Robert J. Soiffer, Lorenzo Trippa, Gad Getz, Donna Neuberg, Irene M. Ghobrial - Nature Communications 2020 cited by 166

  12. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 164

  13. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease

    Authors: , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2019 cited by 201

  14. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research

    Authors: , , , , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2022 cited by 132

  15. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Madan Jagasia, Yi‐Bin Chen - Journal of Clinical Oncology 2017 cited by 318

  16. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2021 cited by 141

  17. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 997

  18. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo

    Authors: , , , , , , , , , , , - Blood 2006 cited by 735

  19. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide

    Authors: , , , , , , , , , , , , , , , , , - Blood Advances 2021 cited by 109

  20. Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1 -Mutated Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 cited by 50

  21. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sacha Gnjatic, Kenneth J. Livak, Jennifer Altreuter, Franziska Michor, Robert J. Soiffer, Jacqueline S. Garcia, Catherine J. Wu - Blood 2023 cited by 50

  22. Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

    Authors: , , , , , , , , , , , , , , - JAMA 2009 cited by 882

  23. Hepatic Veno-Occlusive Disease following Stem Cell Transplantation: Incidence, Clinical Course, and Outcome

    Authors: , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2009 cited by 596

  24. Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2021 cited by 59